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D iabetic retinopathy is a serious complication of diabetes and can 
have severe debilitating effects 
on lifestyle, work and 
relationships. In the UK 
diabetic retinopathy remains 
the main cause of visual 
impairment and registered 
blindness in people under 
65 years of age (Bunce and 
Wormald, 2006; Kumar et al, 
2006). This is despite evidence 
that 60–80% of visual loss is 
preventable by laser treatment 
(Dineen et al, 2008).
To be effective treatment 
for retinopathy needs to be 
given at the appropriate stage 
of the disease, often before 
symptoms have developed; 
thus the importance of 
screening to detect the signs 
of retinopathy before they 
progress (Arun et al. 2005).
The prevalence and 
incidence of type 1 and type 2 
diabetes continues to rise, 
although type 2 diabetes may 
be preventable in many cases 
(Amos et al, 1997; Yorkshire 
and Humberside Public 
Health Observatory, 2009; 
Tuomilehto et al, 2001). Data 
from large studies of the 
microvascular complications 
of diabetes, demonstrate that 
diabetic retinopathy can be 
prevented and managed 
effectively through good 
management (Diabetes 
Control and Complications 
Trial (DCCT) 1993; United 
Kingdom Prospective Diabetes 
Study (UKPDS), 1999). 
Results from the UKPDS 
show that a reduction in 
HbA1c reduces the risk of 
microvascular complications 
by up to 21% (P<0.0001) 
(Stratton et al, 2000) 
(Figure 1).
Progression of 
retinopathy
In diabetes there is 
considerable fluctuation in the 
blood glucose levels and 
abnormally high levels have 
an effect on the small blood 
vessels (capillaries) of the 
eyes, kidneys and those that 
feed the nerves. As a result, 
the capillary wall becomes 
thickened in small areas and 
forms microaneursyms, which 
eventually burst, causing 
haemorrhage. 
If enough of this abnormal 
physiology occurs, the organs 
affected do not receive 
enough blood supply to 
function properly, which leads 
to triggering of ischaemic and 
scarring responses.
Diabetic retinopathy is a 
progressive disease and is 
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Assessment of retinopathy
Warren Gillibrand and Phil Holdich explain the importance of screening all patients with diabetes annually for 
retinopathy as in the majority of cases effective treatment can be given to maintain visual function  
classified in four main stages: 
background, pre-proliferative, 
proliferative, and advanced 
retinopathy.
Background 
retinopathy
The term ‘background 
retinopathy’ is used to 
describe the appearance of 
microanuerysms and 
haemorrhages on fundus 
examination, commonly 
termed ‘dot and blot 
haemorrhages’ (Figure 2). 
It is important to consider 
what having background 
retinopathy means for the 
person with diabetes. 
Background retinopathy 
will not result in visual 
symptoms. However, it is 
important to consider how 
effectively the patient is 
managing his/her diabetes by 
monitoring HbA1c and blood 
pressure levels. A lifestyle or 
treatment change may be 
Figure 2. Fundus of a person with diabetes, showing the characteristic 
‘dot’ and ‘blot’ haemorrhages in background retinopathy.
Figure 1. Lowering HbA1c reduces the risk of diabetes complications in 
people with type 2 diabetes (UKPDS 35) (Stratton et al, 2000)
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needed to improve control.
Practice indicators
 ➤ Ensure the patient is under 
an annual photographic 
screening programme for 
diabetic eye disease. 
Patients with background 
retinopathy only need to be 
re-screened once a year and 
do not need referral to an 
ophthalmology service
 ➤Agree changes to a shared 
care plan for improved 
diabetes management
 ➤Check that the retinopathy 
level is recorded on the 
patient record system.
Pre-proliferative 
retinopathy
Pre-proliferative retinopathy 
indicates signs of ischaemia,  
i.e. tissue death, resulting 
from the loss of blood supply 
to those affected areas of the 
retina. Features include cotton 
wool spots—small areas of 
ischaemia on the retina 
comprising venous beading 
and reduplication or looping 
of blood vessels, which have 
become abnormal in 
appearance—and intraretinal 
microvascular abnormalities, 
which present as tortuous 
dilated blood vessels caused 
by retinal ischaemia.
Pre-proliferative retinopathy 
presents with no visual 
symptoms, but is considered 
hazardous and a precursor to 
more severe sight-threatening 
eye disease. Pre-proliferative 
retinopathy is divided into 
mild, moderate and severe, 
indicating a progression 
toward proliferation.
Practice indicators
 ➤Review patient 
management and shared 
care plan-consider changes 
to improve control 
 ➤ The patient needs to be 
under regular (3-6 months) 
ophthalmology service 
review. 
 ➤Check that the retinopathy 
level is recorded on the 
patient record data system. 
Proliferative retinopathy
Proliferative retinopathy is the 
manifestation of neovascular 
growth either in the 
peripheral fundus or at the 
optic disc (Figure 3). This 
occurs when retinal blood 
supply is no longer sufficient, 
resulting in abnormal vessel 
growth. These new vessels, 
however, are fragile and do 
not follow normal anatomical 
routes. They are prone to 
bleed, causing pre-retinal 
haemorrhage or vitreous 
haemorrhage. Visual loss may 
be complete or partial in the 
affected eye. However, before 
this occurs the patient may 
not experience any symptoms, 
unaware that severe sight 
threatening eye disease has 
developed. 
Until the blood vessels 
bleed the patient may be 
unaware that he/she has sight-
threatening eye disease, as 
there may be no visual 
symptoms. 
Practice indicators
 ➤ If proliferative retinopathy 
is picked up by screening, 
the patient should be 
referred urgently for laser 
treatment by 
ophthalmology services. 
Laser treatment is the 
intervention that prevents 
partial sight registration 
and blindness in diabetes. 
It is highly effective 
working in up to 90% of 
patients (Dineen et al, 
2008). The laser burns and 
destroys the peripheral 
parts of the retina, which 
stops the proliferation of 
new vessel growth and 
concentrates the blood 
supply to the important 
central areas of the retina, 
the macula
 ➤ If the vessels bleed, laser 
and possibly surgery may 
be required to clear the 
blood. However, the 
prognosis for retaining 
vision is adversely affected 
by continued new vessel 
bleeding and can lead to 
the next ‘end stage’ of 
severe advanced 
retinopathy.
Advanced retinopathy
‘Advanced retinopathy’ is the 
term used to describe the late 
complications of neo-vascular 
growth. The new vessels are 
eventually accompanied by 
fibrous proliferation, which 
contracts causing traction and 
retinal detachment. The visual 
prognosis for people with 
advanced stage retinopathy is 
poor, usually resulting in 
blindness or partial sight 
registration. 
Having advanced 
retinopathy usually means 
that the patient will be 
registered blind or partially 
sighted. As a consequence, the 
patient may only be able to 
see vague shapes, light and 
dark or nothing at all. Most 
people retain some sight 
despite being registered blind.
Practice indicators
 ➤Appropriate support 
services referrals, e.g. to 
social services, guide dogs 
for the blind, RNIB
 ➤Re-organization of a 
shared-care plan and 
review of diabetes 
management 
 ➤Appropriate psychological 
monitoring and support
 ➤ Specialist ophthalmic 
services
 ➤Referral to a low visual 
aids clinic, either via the 
local ophthalmology 
department or RNIB.
Maculopathy
One further classification is 
used in the detection of 
diabetic retinopathy. 
Maculopathy is the 
manifestation of diabetic 
Figure 3. Fundus of a person with diabetes showing neo-vascularization 
associated with proliferative retinopathy.
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retinopathy which occurs in 
the macular area of the 
fundus, which is used for 
detailed vision. Signs of 
maculopathy are exudates 
and clinically significant 
macular oedema. Oedema is 
sight threatening and is 
usually manifest to the patient 
as blurred vision. It can only 
be detected by stereoscopic 
examination of the fundus.
Health education 
Health education is a vital 
strategy which can empower 
patients to seek annual eye 
checks and give patients the 
encouragement and knowledge 
to take control of their 
diabetes by following a 
healthy lifestyle. 
Health education is 
necessary but must be tailored 
to individuals’ needs in the 
context of their particular 
lifestyle with the differing 
coping and cognitive 
mechanisms considered, i.e. a 
psycho-educational approach 
(Duke et al 2009). A variety 
of sources of health 
information are available for 
health professionals from 
each of the devolved health 
services (Table 1). 
Strategies for health 
education include individual 
education sessions, group 
talks and use of local health 
promotion services. 
Practice indicators
 ➤ Inform patients with 
diabetes that they should 
be annually screened by 
photography for signs of 
eye disease, unless they are 
already under the care of a 
consultant specialist 
ophthalmic service. 
 ➤Continue to instigate 
lifestyle change motivators 
and agreed shared care 
plans based on the patients 
quality of life indicators, to 
aid in improved diabetes 
control including blood 
pressure. 
 ➤ Patients should know that 
diabetes can cause 
blindness but is 
preventable if detected 
early enough. 
Current NHS Policy
The NSPDR (2008) 
recommends fully validated 
and tested screening 
programme, coordinated and 
funded by the local health 
authority and primary care 
trusts, using a digital 
photography system to screen 
all people with diabetes 
annually.
The National Service 
Framework for Diabetes 
(Department of Health (DH), 
2002) set an initial target of 
establishing a screening 
programme for the detection 
of diabetic retinopathy that 
would offer annual screening 
to all people with diabetes by 
2007 (Gillibrand et al, 2004; 
NSPDR, 2008). This first 
target was based on the level 
of current evidence and 
services available for the 
detection of diabetic 
retinopathy and is detailed in 
standard 10 of the national 
service framework (DH, 2002. 
Current NHS reporting 
recommends that all people 
with diabetes have the 
opportunity for screening, 
however the target uptake of 
90% is not always achieved 
(NSPDR, 2008).  
Patient experience 
It is important to consider the 
patient’s experience and the 
benefits of attending the 
screening programme. There 
have been some attempts in 
the literature to explore 
reasons for non-attendance to 
screening which have 
revealed; fear, lack of 
knowledge, economics, poor 
access; social deprivation; 
duration of diabetes; and 
equity (Gillibrand et al. 
2000a; 2001; Hartnett et al, 
2005; Millett and Dodhia, 
2006; Leese et al, 2008). 
Methods to improve 
attendance have focused on 
group education sessions 
using local networks, 
culturally sensitive education, 
accessibility, and conducting 
regular equity audits 
(Livingston et al, 1998; 
Gillibrand et al, 2000b; 
Millett and Dodhia, 2006). 
The NSPDR (2008) has 
published guidelines and 
England: National Screening 
Programme for Diabetic 
Retinopathy
www.retinalscreening.nhs.uk/pages
Northern Ireland: Diabetic 
Retinopathy Screening 
www.dhsspsni.gov.uk/public_
health_diabetic_retinopathy
Scotland: National Diabetes 
Retinopathy Screening 
Collaborative  
www.ndrs.scot.nhs.uk
Wales: Diabetic Retinopathy 
Screening Service for Wales
http://tinyurl.com/3a2423w
Table 1. Resources
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educational material for 
practitioners in England to 
use in supporting and 
maintaining an acceptable 
level of attendance. In 
Scotland, the Manual for the 
Diabetic Retinopathy 
Screening Programme for 
Scotland is available online 
from the (National Diabetes 
Retinopathy Screening, 2010).
Conclusions
There is a good evidence base 
to support early detection via 
screening and treatment of 
diabetic retinopathy (National 
Institute for Health and 
Clinical Excellence (NICE), 
2008). With good service 
development and 
implementation, many 
patients can avoid progressing 
to advanced retinopathy and 
suffering visual impairment. 
Robust clinical trials have 
demonstrated that people 
with type 1 and type 2 
diabetes can reduce the 
incidence and severity of 
complications through strict 
control of their diabetes 
(DCCT, 1993; UKPDS, 1998). 
Therefore if people with 
diabetes can maintain stable 
blood glucose levels they will 
be more likely not to develop 
complications and will reduce 
the severity. The practice 
nurse has an important role in 
educating patients about 
diabetic retinopathy, to ensure 
that all their patients attend 
annual retinopathy screening, 
and provide diabetes 
management support, to 
prevent complications of 
diabetes developing.
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Key Points
 ➤ All people with diabetes 
should be screened annually 
for diabetic retinopathy by 
a validated digital 
photography method
 ➤ Patients should be 
supported by the practice 
nurse in managing their 
diabetes to prevent diabetic 
retinopathy
 ➤ There is good evidence that 
the majority of diabetic 
retinopathy can be 
effectively treated to 
maintain visual function, if 
detected early enough
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